SCHEMBL4243389

SCHEMBL4243389

NS(=O)(=O)c1ccc2c(c1)C(=O)CC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 11/20 0.55
CA2 P00918 11/20 0.55
CA12 O43570 7/20 0.55
CA7 P43166 3/20 0.55
CA14 Q9ULX7 3/20 0.55
PBRM1 Q86U86 1/20 0.52
CA9 Q16790 7/20 0.47
PKM P14618 2/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
ADRA2A P08913 1/20 0.47
PNMT P11086 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
TDP2 O95551 1/20 0.44
NSD2 O96028 1/20 0.44
HK1 P19367 1/20 0.44
PAX8 Q06710 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135031 0.89 CA1 (0.66) CA1CA2CA12CA7CA14
SCHEMBL29649377 0.89 CA1 (0.66) CA1CA2CA12CA7CA14
SCHEMBL4235756 0.85 CASP1 (0.56) CA1CA2CA12CA7CA14
SCHEMBL30232456 0.85 CASP1 (0.56) CA1CA2CA12CA7CA14
SCHEMBL1003926 0.81 PBRM1 (0.52) PBRM1PNMTCASP1CASP7HSD17B10
SCHEMBL6205829 0.81 PBRM1 (0.52) CA1CA2CA12CA7CA14
Hydrochloric Acid SCHEMBL28058141 0.80 PBRM1 (0.55) CA1CA2CA12CA7CA14
SCHEMBL8870208 0.77 PBRM1 (0.47) PBRM1ALDH1A1PNMTPOLBCASP1
SCHEMBL29649370 0.75 CA1 (0.66) CA1CA2CA12CA7CA14
SCHEMBL20638456 0.75 CA1 (0.66) CA1CA2CA12CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118323-A1 ANTITUMOR BENZOYLSULFONAMIDES MADER MARY MARGARET 2009-05-07 US disclosed
EP-1565438-B1 ANTITUMOR BENZOYLSULFONAMIDES LILLY CO ELI (US) 2007-10-17 EP disclosed
US-7282595-B2 Antitumor benzoylsulfonamides ELI LILLY AND COMPANY (US) 2007-10-16 US disclosed
US-20060106053-A1 Antitumor benzoylsulfonamides ELI LILLY AND COMPANY 2006-05-18 US disclosed
EP-1565438-A1 ANTITUMOR BENZOYLSULFONAMIDES ELI LILLY AND COMPANY (US) 2005-08-24 EP disclosed
WO-2004048329-A1 ANTITUMOR BENZOYLSULFONAMIDES ELI LILLY AND COMPANY (US) 2004-06-10 WO disclosed
EP-0508586-B1 Substituted indenyl compounds FGN INC (US) 1995-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118323-A1 ANTITUMOR BENZOYLSULFONAMIDES HCCS, GLS2, GLS CA1 428/4885CA2 1594/4885CA12 122/4885
US-20060106053-A1 Antitumor benzoylsulfonamides HCCS, GLS2, GLS CA1 428/4885CA2 1594/4885CA12 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.